| abstract |
According to aspects of the present disclosure, methods and compositions are provided which relate to treating cancer in a subject in need thereof, including: administering 1) an anti-cancer immune therapeutic agent, and 2) a stimulator of p53 levels and/or p53 activity, as a combination formulation or separately, thereby increasing levels and/or activity of p53, and activating NK cell activity in the cancer, providing therapeutic benefits, converting a “cold tumor” into a “hot tumor” leading to a TME responsive to immunotherapy via tumor cell recognition and killing that is not dependent on T-cell mediated immunity. |